Polaryx Therapeutics, Inc. PLYX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 661.00K | 1.28M | 351.00K | 460.00K | 408.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.38M | 1.96M | 911.00K | 974.00K | 884.00K |
| Operating Income | -1.38M | -1.96M | -911.00K | -974.00K | -884.00K |
| Income Before Tax | -1.38M | -2.54M | -1.50M | -1.43M | -1.01M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.38M | -2.54M | -1.50M | -1.43M | -1.01M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.38M | -2.54M | -1.50M | -1.43M | -1.01M |
| EBIT | -1.38M | -1.96M | -911.00K | -974.00K | -884.00K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.03 | -0.05 | -0.03 | -0.03 | -0.02 |
| Normalized Basic EPS | -0.02 | -0.03 | -0.02 | -0.02 | -0.01 |
| EPS Diluted | -0.03 | -0.05 | -0.03 | -0.03 | -0.02 |
| Normalized Diluted EPS | -0.02 | -0.03 | -0.02 | -0.02 | -0.01 |
| Average Basic Shares Outstanding | 48.28M | 47.22M | 46.87M | 45.79M | 44.67M |
| Average Diluted Shares Outstanding | 48.28M | 47.22M | 46.87M | 45.79M | 44.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |